Commonwealth Equity Services
CRDL

Commonwealth Equity Services’s Cardiol Therapeutics CRDL Stock Holding History

Commonwealth Equity Services’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15K Buy
11,100
+370
+3% +$380 ﹤0.01% 4268
2025
Q4 		$10.2K Buy
10,730
+130
+1% +$136 ﹤0.01% 4263
2025
Q3 		$11K Buy
+10,600
New +$12.9K ﹤0.01% 4221

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Commonwealth Equity Services's CRDL Position: Q1 2026 in Review

Commonwealth Equity Services increased its Cardiol Therapeutics (CRDL) stake by 3.4% in Q1 2026, buying an estimated $380 and bringing the position to 11,100 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #4268.

Commonwealth Equity Services first reported a position in CRDL in Q3 2025 and has held it in 3 quarters since. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

  • Commonwealth Equity Services held 11,100 shares of Cardiol Therapeutics worth $15K as of Q1 2026.
  • Commonwealth Equity Services bought 370 Cardiol Therapeutics shares in Q1 2026, an estimated $380.
  • Cardiol Therapeutics made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q1 2026, its #4268 holding.
  • Commonwealth Equity Services first reported a position in Cardiol Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on Commonwealth Equity Services's 13F filing for Q1 2026, filed 27 Apr 2026.